Pinnacle Associates’s Haemonetics HAE Stock Holding History

Pinnacle Associates’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.48M	Buy	19,713 +9,257	+89%	+$595K	0.02%	466
2026 Q1	$589K	Buy	+10,456	New	+$681K	0.01%	618

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pinnacle Associates's HAE Position: Q2 2026 in Review

Pinnacle Associates increased its Haemonetics (HAE) stake by 89% in Q2 2026, buying an estimated $595K and bringing the position to 19,713 shares worth $1.48M. The position accounts for 0.02% of the portfolio, ranked #466.

Pinnacle Associates first reported a position in HAE in Q1 2026 and has held it in 2 quarters since. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

Pinnacle Associates held 19,713 shares of Haemonetics worth $1.48M as of Q2 2026.
Pinnacle Associates bought 9,257 Haemonetics shares in Q2 2026, an estimated $595K.
Haemonetics made up 0.02% of Pinnacle Associates's portfolio in Q2 2026, its #466 holding.
Pinnacle Associates first reported a position in Haemonetics in Q1 2026 and has held it in 2 quarters since.
329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Pinnacle Associates's 13F filing for Q2 2026, filed 3 Aug 2026.